Detail akcie Biogen Idec online

Business Summary: Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Biogen Inc revenues increased 2% to $9.89B. Net income decreased 21% to $1.29B. Revenues reflect United States segment increase of 13% to $3.73B, United states-Revenues from anti-CD20 therapeutic segment increase of 6% to $1.86B, Rest of World-Other revenues segment increase of 12% to $732.9M. Net income was offset by Biopharmaceutical segment income decrease of 17% to $1.86B.